MAR001, a monoclonal antibody by Marea Therapeutics, significantly reduced triglycerides by up to 72.2% in patients with severe hypertriglyceridemia (sHTG) during the Phase 2b TYDAL-TIMI 78 trial, without worsening blood sugar control. The trial met all primary endpoints, showing sustained triglyceride and remnant cholesterol reductions across doses, and a safety profile comparable to placebo. These results, presented at AHA 2026 and published in NEJM, support further development of MAR001 and its extended version MAR005, with Part B of the trial now enrolling sHTG patients. This treatment could help prevent pancreatitis in sHTG patients, many of whom also have diabetes, without increasing cardiovascular risks.
The Marea Therapeutics MAR001 trial results provide context for health sector interest. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 20:42 WIB: out of 150 priced health-sector US stocks, 110 rose and 27 fell. Notable movers include ARWR at USD 53.74 with a -7.59% change, FLNA at USD 0.48 with a +6.01% change, and CLPT at USD 8.99 with a +4.53% change.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
